profit from every $100 of sales.
$0$100
Jupiter Neurosciences
$1.76-5.38% today
+34.4% in 1 year
1-year low $0.451-year high $34.88
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Jupiter Neurosciences sold, what it kept, and what it did with the cash.
Sales went from $233,281 in 2022 to $21,796 in 2025, with -$8.64 million of profit last year.
SalesProfit
Jupiter Neurosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Jupiter Neurosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Jupiter Neurosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | 0 | |
| -3 | -4 | -3 | -9 | |
| -4 | -5 | -2 | -9 | |
| -5 | -5 | -2 | -9 | |
| -0.15 | -0.18 | -0.08 | -0.25 | |
| – | – | – | 80.6% | |
| -1,471.4% | – | – | -40,873.2% | |
| -2,125.2% | – | – | -39,662.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 6 | 6 |
| Cash | 0 | 0 | 4 | 4 |
| Total debt | 2 | 2 | 0 | 5 |
| Total liabilities | 7 | 6 | 2 | 7 |
| -7 | -6 | 4 | -2 | |
| 33 | 26 | 29 | 35 | |
| – | – | -39.4% | -194.3% | |
| 69.4% | 82.5% | -58.5% | 471.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -0 | -4 | -5 | |
| – | – | – | – | |
| -1 | -0 | -4 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 2 | 2 |
Valuation
- –
- 29.3×
- –
- -6.3×
- 106.5×
- –
- –
- -233.3%
- -372.5%
- 0.0%
Profitability
- 80.6%
- -40,873.2%
- -39,662.8%
- -39,359.9%
- -255.4%
- 4.5%
- -1,314.7%
- -155.4%
- 486.3%
- –
Growth
- −54.6%
- –
- −38.4%
- –
- +38.2%
Financial health
- –
- -2.90
- 95.6%
- –
- 0.65
- 0.63
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 887
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.06 | -0.05 | −20.0% |
| Apr 1, 2026 | -0.07 | -0.07 | +0.0% |
| Nov 14, 2025 | -0.07 | -0.08 | +12.5% |
| Aug 18, 2025 | -0.07 | -0.07 | +0.0% |
| May 15, 2025 | -0.05 | -0.03 | −66.7% |
| Mar 28, 2025 | -0.05 | -0.02 | −150.0% |
| Dec 23, 2024 | -0.02 | – | – |
| Jun 30, 2024 | 0.01 | – | – |
News
Jupiter Neurosciences announces pricing of $2M registered direct offeringSeeking Alpha · Aug 21, 2026The newest story we have is from Aug 21, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
5No pass
Philip Fisher
49No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
44No pass
Questions about Jupiter Neurosciences
Is Jupiter Neurosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jupiter Neurosciences AI analysis
What does Jupiter Neurosciences do?
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is in Biotechnology.
Does Jupiter Neurosciences pay a dividend?
No. Jupiter Neurosciences does not pay a dividend at the moment.
Is Jupiter Neurosciences stock halal?
No. Jupiter Neurosciences does not pass our halal screen: its debt is 229% of its market value, at or above the 33% limit. How we check
How has Jupiter Neurosciences stock done over the past year?
Up 34.4% over the past twelve months, to $1.76. It traded between $0.45 and $34.88 and is 95.0% below its high.
Who are Jupiter Neurosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Jupiter Neurosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.